Twice as many people survived cancer in 2012 than did in 1992. Today, the National Cancer Institute (NCI) is poised to further accelerate the rate of scientific discovery and reduce the burden of cancer in the United States and around the world.

Program Overview:
NCI SBIR & STTR: Advancing the Commercialization of New Cancer Innovations
The NCI continues to develop new funding opportunities that adapt to changes in the way that science is conducted. Supporting the best scientists is paramount. The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early stage companies, providing over $110M in fiscal year 2014 to develop next generation technologies.

Presenting at this event will be Ming Zhao, Ph.D., Program Director, SBIR Development Center, National Cancer Institute. Dr. Zhao will cover:

• Overview of SBIR/STTR eligibility requirements
• NIH SBIR/STTR process and new cancer-focused grant funding opportunities from NCI
• New NCI SBIR/STTR initiatives such as NIH Innovation Corps (I-Corps™) Team Training Pilot Program
• NCI Investor Forum to help NCI SBIR-funded companies to connect with investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries
• Practical strategies on how to successfully submit competitive research proposals

Following the presentations selected companies will have the opportunity to meet one-on-one with directors. To be considered for a one-on-one meeting, please contact Brittany Connors by April 30 with your name, company name, and a short executive summary.

Agenda:
10:00am | Registration and Networking
10:30am | Presentation and Q&A
12:00pm | Networking Lunch
1:00-4:30pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please contact Brittany Connors by April 30 with your name, company name, and a short executive summary.

National Cancer Institute Participating Representative:
Ming Zhao, Ph.D. | Program Director, SBIR Development Center, National Cancer Instituteread bio»

About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government\’s principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until May 7th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
*Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please contact Brittany Connors by April 30 with your name, company name, and a short executive summary.

Venue:
Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd.
South San Francisco, CA

National Cancer Institute Representative\’s Biography:
Ming Zhao, Ph.D. | Program Director, SBIR Development Center, National Cancer Institute
Ming Zhao, Ph.D., is a Program Director in the SBIR Development Center at the National Cancer Institute (NCI). In this role, Dr. Zhao develops and manages SBIR/STTR programs and contracts focused on cancer therapeutics, molecular diagnostics and medical imaging. Prior to his appointment at SBIR, Dr. Zhao was a Program Director in the Center to Reduce Cancer Health Disparities (CRCHD) at the NCI. During his tenure at CRCHD, he managed various NCI/NIH programs such as Community Networks Program Centers (CNPC, a program with a total of $117M & 23 Centers) and Geographical Management of Cancer Health Disparities Program (GMaP) as well as R01/R21 grants. Before Dr Zhao joined NCI, he worked as a senior scientist at the GE Global Research Center and as a scientist at Pfizer. Dr. Zhao has broad industrial experience in the development of molecular medicine for early diagnosis of cancer, molecular imaging, the application of human embryonic stem cells, bioinformatics, DNA cloning without cells, biological assay development for bio-compatibility in healthcare applications, and drug discovery in cancer, diabetes, obesity, and central nervous system diseases. Dr. Zhao received his BS/MS degrees from Shandong University, China, and his Ph.D. in molecular biology and biochemistry from the Department of Biological Sciences, Wayne State University. He carried out postdoctoral research at both the University of Michigan Medical School and Wayne State University. Dr. Zhao has published over fifty scientific publications and industrial/technical reports. He has also filed/published eight patents.

About the Meet with… Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, DARPA\’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Poliwogg, and OrbiMed.